Posts by: Joana Carvalho, MSc

Joana Carvalho, MSc

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.

November 18, 2019November 18, 2019

China Opens Blood Disease Platform, Collecting Patient Data to Improve Research and Treatment

News

The Analysis Group has partnered with China’s Institute of Hematology & Blood Diseases Hospital (IHBDH) to create the first blood disease research platform in that country. The new platform, called the ... Read more

October 25, 2019October 25, 2019

Elimination of HCV in People with Bleeding Disorders Surpasses WHO Goals, Study Finds

News

Direct‐acting antiviral (DAA) therapy is especially effective at eliminating hepatitis C virus (HCV) in people with bleeding disorders, including hemophilia, a study has found. The study, “Elimination of hepatitis ... Read more

October 14, 2019October 14, 2019

Novo Nordisk Partners with Bluebird Bio to Develop New Gene Therapies for Hemophilia, Other Disorders

News

Novo Nordisk has entered into a collaboration agreement with Bluebird Bio to develop new therapies based on gene editing for a series of genetic disorders, including hemophilia. The companies ... Read more

October 11, 2019October 11, 2019

FDA Approves Wilate for Adults and Adolescents With Hemophilia A

News

The U.S. Food and Drug Administration (FDA) has approved Wilate as a prophylactic (preventive) and on-demand treatment for bleeding episodes in adults and adolescents with hemophilia A. Wilate, developed ... Read more

October 9, 2019October 9, 2019

Muscle Rehabilitation Exercises Safe, Effective for People with Severe Hemophilia, Study Suggests

News

Moderate muscle rehabilitation exercises — based on the use of elastic bands or training machines — are safe and effective for people with severe hemophilia receiving prophylactic (preventive) treatment, ... Read more

October 7, 2019October 23, 2019

Work, Relationship Issues Affect Health-related Quality of Life, Pain in Adults with Hemophilia B, Study Says

News

Problems at work, limited engagement in recreational activities, and less relationship satisfaction contribute to a lower health-related quality of life (HRQoL) and greater pain severity, as reported by adults ... Read more

September 18, 2019September 18, 2019

NovoSeven-Hemlibra Combo Not Linked to Higher Risk of Thrombosis, Data Show

News

Simultaneous use of NovoSeven (recombinant factor VIIa, rFVIIa) and Hemlibra (emicizumab) in patients with hemophilia A is not associated with higher risk of thrombosis, new analysis of the Phase ... Read more

September 11, 2019September 11, 2019

Hemophilia Three Times More Prevalent Worldwide Than Thought, Study Finds

News

Scientists report that hemophilia is three times more prevalent in men worldwide than previously thought and still associated with a poorer life expectancy, especially in low-income countries. Findings of ... Read more

September 4, 2019September 4, 2019

uniQure Completes Enrollment Early for Phase 3 Trial of AMT-061 Gene Therapy

News

uniQure has achieved its target patient enrollment goal ahead of schedule for its ongoing Phase 3 HOPE-B trial. The trial is assessing the safety and efficacy of AMT-061 (etranacogene ... Read more

July 29, 2019July 29, 2019

BioMarin Preparing to Submit Marketing Authorization Applications for Valoctocogene Roxaparvovec

News

BioMarin Pharmaceuticals is planning to submit marketing authorization applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) seeking approval of valoctocogene roxaparvovec, its ... Read more

Pin It on Pinterest